|
|
|
|
|
| Saturday, 14th May 2005 |
||
| 8.00 – 12.00pm Poster Discussion Session Level 2, Hall F3 |
Brain Tumor Group Multicentre Phase II Study of Imatinib Mesylate (Glivec®) in Patients With Recurrent Anaplastic Oligodendroglioma (AOD)/Mixed Oligoastrocytoma (MOA) and Anaplastic Astrocytoma (AA)/Low Grade Astrocytoma (LGA): An EORTC: New Drug Development Group (NDDG) and Brain Tumor Group (BTG) Study). Presenter: M. van den Bent, MD Abstract N°: 1517 |
|
| 12.15 – 12.30pm Oral Abstract Presentation Session Level 4, Valencia Room, 415B |
Soft Tissue and Bone Sarcoma Group Assessment of molecular determinants of development and treatment efficacy in radiation induced sarcoma (RIS). EORTC STBSG Translational Research Project 01/01. Presenter: P. Hohenberger, MD, PhD Abstract N°: 9008 |
|
| 1.00 – 1.15pm Oral Abstract Presentation Session Level 2, Hall F5 |
Lymphoma Group First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). Presenter: E.M. Noordijk, MD, PhD Abstract N°: 6505 |
|
| 1.00 – 5.00pm Poster Discussion Session Level 2, Hall F3 |
Quality of Life Group An international prospective study of the psychometric properties of the EORTC satisfaction with care measure (EORTC QLQ SAT-32). Presenter: A. Brédart Abstract N°: 6030 |
|
| 2.00 – 6pm Poster Discussion Session Level 2, Hall C |
Chronotherapy Group Independent prognostic value of the rest/activity circadian rhythm on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCC) receiving first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin: a companion study to EORTC 05963. Presenter: C. Garufi, MD Abstract N°: 3553 |
|
| 2.00 – 6pm Poster Discussion Session Level 2, Hall C |
Chronotherapy Group Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results from EORTC randomized phase III trial 05963. Presenter: F. Lévi, MD, PhD Abstract N°: 3587 |
|
| 2.00 – 6pm Poster Discussion Session Level 2, Hall C |
Gastrointestinal Tract Cancer Group On behalf of the EORTC Gastrointestinal Tract Cancer Group: The value of patient-reported symptoms as prognostic factors for survival in advanced colorectal cancer. Presenter: F. Efficace, PhD Abstract N°: 3585 |
|
| Sunday, 15th May 2005 |
||
| 8.00 – 12.00pm Poster Discussion Session Level 2, Hall F4 |
Chronotherapy Group Quality of life (QoL) correlates with the rest/activity circadian rhythm (RAR) in patients (pts) with metastatic colorectal cancer (MCC) on first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin : an international multicenter study (EORTC 05963). Presenter: P.F. Innominato, MD Abstract N°: 8029 |
|
| 8.00 – 12.00pm Poster Discussion Session Level 2, Hall C |
Brain Tumor and Radiotherapy Groups On behalf of the EORTC Brain tumor and Radiotherapy groups and NCIC: Predicting survival using health-related quality of life scores in glioblastoma cancers. Findings from an international Phase III randomized controlled trial. Presenter: A. Bottomley, PhD Abstract N°: 9601 |
|
| 8.00 – 12.00pm Poster Discussion Session Level 2, Hall C |
Gastrointestinal Tract Cancer and Receptor and Biomarker Groups Quality control (QC) tissue array for the prospective evaluation of translational research projects. A program of the EORTC GI and RB Groups. Presenter: M.P. Lutz, MD Abstract N°: 9600 |
|
| Monday, 16th May 2005 |
||
| 8.00 – 12.00pm Poster Discussion Session Level 2, Hall C |
Soft Tissue and Bone Sarcoma Group Exatecan (DX-8951f), a new topoisomerase I - inhibitor is inactive in heavily pretreated patients (pts.) with advanced soft tissue sarcoma (STS): a phase II - study of the EORTC Soft Tissue and Bone Sarcoma Group. Presenter: P. Reichardt Abstract N°: 9058 |
|
| 9.15 – 9.30am Oral Abstract Presentation Session Level 2, Hall A2 |
Radiotherapy Group Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial. Presenter: J.F. Bosset, MD Abstract N°: 3505 |
|
| 1.00 – 1.15pm Oral Abstract Presentation Session Level 2, Hall A2 |
Lung Group A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941). Presenter: J.P. van Meerbeeck, MD, PhD Abstract N°: LBA 7015 |
|
| 1.00 – 5pm Poster Discussion Session Level 2, Hall F3 |
Genito-Urinary Group Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors. Presenter: C.N. Sternberg, MD, FACP Abstract N°: 4528 |
|
| 4.00 – 4.15pm Plenary Session III Level 2, Hall D2 |
Gastrointestinal Tract Cancer Group Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). Presenter: E. van Cutsem, MD, Phd Abstract N°: LBA8 |
|
| Tuesday, 17th May 2005 |
||
| 8.00 – 12.15pm Poster Discussion Session Level 3, 315 A |
Gastrointestinal Tract Cancer Group Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC phase III study 40015. Presenter: C.H. Köhne, MD Abstract N°: 3525 |
|
| 8.00 – 12.15pm Poster Discussion Session Level 3, 315 A |
Gastrointestinal Tract Cancer Group Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983. Presenter: B. Nordlinger, MD Abstract N°: 3528 |
|
| 8.30 – 8.45am Oral Abstract Presentation Session Level 2, 230 A |
Brain Tumor Group First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. Presenter: M.J. van den Bent, MD Abstract N°: 1503 |
|